{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:06Z","timestamp":1793946426512,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105520","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:42:40Z","timestamp":1785912160000},"page":"105520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["mRNA vaccines targeting HPV E6\/E7: A new frontier in cervical cancer immunotherapy"],"prefix":"10.1016","volume":"226","author":[{"given":"Somayeh","family":"Aftabsavad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Arashkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Shokrgozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Abbas","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Karimipoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2026.105520_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105520_bib2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105520_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105520_bib4","article-title":"FDA Fast Track designation for BNT113 in HPV16-positive head and neck cancer","author":"BioNTech","year":"2026","journal-title":"N. Release"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105520_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105520_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc3246","article-title":"The determinants of tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105520_bib7","doi-asserted-by":"crossref","first-page":"14935","DOI":"10.2147\/IJN.S565558","article-title":"mRNA-LNP vaccines targeting HPV E6\/E7: advances and challenges","volume":"20","author":"Cao","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105520_bib8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105520_bib9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105520_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105520_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20050369","article-title":"Molecular biology of human papillomavirus infection and cervical cancer","volume":"110","author":"Doorbar","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.critrevonc.2026.105520_bib12","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"issue":"4893","key":"10.1016\/j.critrevonc.2026.105520_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.2537532","article-title":"The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105520_bib14","first-page":"1953","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine in preclinical models","volume":"25","author":"Edwards","year":"2017","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105520_bib15","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells","volume":"23","author":"Feltkamp","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105520_bib16","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/adma.201505822","article-title":"Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery","volume":"28","author":"Fenton","year":"2016","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105520_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105520_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105520_bib19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105520_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/1874357901206010249","article-title":"The invisible enemy\u2014how human papillomaviruses avoid recognition and clearance by the host immune system","volume":"6","author":"Grabowska","year":"2012","journal-title":"Open. Virol. J."},{"issue":"9447","key":"10.1016\/j.critrevonc.2026.105520_bib21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105520_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105520_bib23","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"vaccines: current status and future directions","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105520_bib24","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.critrevonc.2026.105520_bib25","article-title":"Therapeutic mRNA vaccines for HPV-associated malignancies: a systematic review","volume":"31","author":"Iqbal","year":"2024","journal-title":"Cancer Control."},{"key":"10.1016\/j.critrevonc.2026.105520_bib26","article-title":"ARC01: First mRNA therapeutic vaccine approved in China for HPV16-positive cancers","volume":"31","author":"Iqbal","year":"2024","journal-title":"Cancer Control."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105520_bib27","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105520_bib28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105520_bib29","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","article-title":"Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity","volume":"70","author":"Kreiter","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105520_bib30","first-page":"175","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration. J Control Release","volume":"263","author":"Liang","year":"2017"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105520_bib31","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105520_bib32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105520_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105520_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12985-024-02397-9","article-title":"mRNA-based therapeutic vaccines for HPV-associated cancers: a comprehensive review","volume":"21","author":"Movahed","year":"2024","journal-title":"Virol. J."},{"issue":"54","key":"10.1016\/j.critrevonc.2026.105520_bib35","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.1038\/sj.onc.1204860","article-title":"Biological activities and molecular targets of the human papillomavirus E7 oncoprotein","volume":"20","author":"M\u00fcnger","year":"2001","journal-title":"Oncogene"},{"issue":"7662","key":"10.1016\/j.critrevonc.2026.105520_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105520_bib37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105520_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105520_bib39","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105520_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.annonc.2024.08.938","article-title":"BNT113 plus pembrolizumab in HPV16-positive recurrent\/metastatic head and neck squamous cell carcinoma: early results from the AHEAD-MERIT trial","volume":"35","author":"Saba","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7662","key":"10.1016\/j.critrevonc.2026.105520_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105520_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105520_bib43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjos\u00e9","year":"2010","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105520_bib44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105520_bib45","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105520_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect. Agents Cancer"},{"issue":"8056","key":"10.1016\/j.critrevonc.2026.105520_bib47","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"Autogene cevumeran in pancreatic ductal adenocarcinoma: T cell responses and clinical outcomes","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105520_bib48","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","article-title":"Scalable mRNA delivery via microfluidic mixing for vaccine applications","volume":"21","author":"Shepherd","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.critrevonc.2026.105520_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Immunomodulation of the tumor microenvironment by HPV E6 and E7 oncoproteins","volume":"9","author":"Smalley Rumfield","year":"2020","journal-title":"ImmunoTargets Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105520_bib50","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"17_","key":"10.1016\/j.critrevonc.2026.105520_bib51","first-page":"LBA9512","article-title":"Three-year recurrence-free survival with mRNA-4157 plus pembrolizumab in resected melanoma: KEYNOTE-942 update","volume":"43","author":"Weber","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105520_bib52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.vaccine.2008.10.078","article-title":"Therapeutic HPV vaccines: current and future directions","volume":"27","author":"Yan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2026.105520_bib53","article-title":"Therapeutic HPV vaccines: a review of the current status and future perspectives","volume":"12","author":"Yousefi","year":"2021","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105520_bib54","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipid nanoparticles for mRNA delivery: design, optimization, and biomedical applications","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105520_bib55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat. Rev. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:42:40Z","timestamp":1793943760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"alternative-id":["S1040842826004075"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105520","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines targeting HPV E6\/E7: A new frontier in cervical cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105520"}}